Record number:
280
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
Most recent risk assessment for medulloblastoma (Council of Europe, 2022):
Childhood medulloblastomas are the CNS primitive tumours that metastasize most frequently outside the CNS. The risk may be increased if prior ventriculo-peritoneal or ventricular-atrial shunts, tumour resection or cranial chemo-/radiotherapy have been performed. Organs from potential donors with medulloblastomas (WHO grade IV) are considered intermediate to high risk for tumour transmission, depending on different international recommendations, which will be adjusted with increasing evidence. They should be used exclusively for transplants where the recipient’s risk of dying while on the waiting list is greater than the risk of tumour transmission.
Time to detection:
5 - 7 months
Alerting signals, symptoms, evidence of occurrence:
Not specified. The only information provided is that 7 organs were transplanted from donors with medulloblastomas and all of the organ recipients developed malignancies. Two recipients died of progressive disease at 26 months post ransplantation, and the third patient was alive with diffuse metastatic disease at last report
Demonstration of imputability or root cause:
Same histological type of tumour in donors and recipients. Risk factor for the transmission of a central nervous system malignancy -ventriculoperitoneal shunt in all three donors. No further specification provided.
Imputability grade:
3 Definite/Certain/Proven
Groups audience:
Suggest new keywords:
Registry series
Decease donor
Suggest references:
aaa